News
Avillion/Merck psoriasis nanobody hits the mark in phase 2
UK biotech Avillion has reported positive mid-stage results with chronic psoriasis drug sonelokimab, which it is developing with Merck KGaA as an alternative to drugs like Novartis' Cosenty
